Main Article Content

Azeen Razzaq
Ali Hassan Sajjad
Areeha Munawar
Shaista Mumtaz
Isma Kauser
Humna Naseer
Ali Asim Dilshad




Objectives: To find out the association of cardiovascular and endocrinological disorders with psoriasis

Materials: In the Department of Dermatology of a tertiary care hospital, a cross-sectional study was carried out from 2022 to 2023 with approval from the hospital's ethical review committee. The current study included fifty psoriasis patients who presented in the dermatology outpatient department of a tertiary care hospital in Lahore as cases. As a control group, fifty patients with skin conditions other than psoriasis were included, and the prevalence of endocrinological and cardiovascular diseases was compared between the two groups. Using SPSS version 16, the Student t test was used to compare the means of different variables. P values less than 0.05 were considered statistically significant.

Result: The gender ratio, mean age, and percentage of smokers were similar in both groups. However, mean BMI was higher in psoriatic patients in comparison to non psoriatic patients. The prevalence of diabetes mellitus, hypertension, decreased HDL, hypertension, and myocardial infarction was higher in psoriatic patients compared to non-psoriatic patients. In comparison to non-psoriatic patients, patients with psoriasis had higher mean blood pressure, mean BMI, mean triglyceride levels (TAG), and mean fasting blood glucose levels (FBGL). In comparison to non-psoriatic patients, the mean value of high density lipoproteins was lower in psoriatic patients.

Conclusion: Raised mean fasting BSR, TAG, low HDL, elevated mean blood pressure, and elevated mean BMI are all statistically positively correlated with psoriasis.

Abstract 112 | pdf Downloads 32


1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899-912.
2. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevelance and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005; 141:1537-41.
3. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32:982-6.
4. Gelfand JM, Neimann AN, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:1735-41.
5. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785–96.
6. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Current opinion in rheumatology. 2008 Jul;20(4):416–22. [Research Support, N.I.H., Extramural Review]
7. National Cholesterol Education Program (US). Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). No. 2. The Program, 2002.
8. Gisondi, P., Fostini, A. C., Fossà, I., Girolomoni, G., & Targher, G. (2018). Psoriasis and the metabolic syndrome. Clinics in dermatology, 36(1), 21–28.
9. Langan, S. M., Seminara, N. M., Shin, D. B., Troxel, A. B., Kimmel, S. E., Mehta, N. N., Margolis, D. J., & Gelfand, J. M. (2012). Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. The Journal of investigative dermatology, 132(3 Pt 1), 556–562.
10. Yamazaki F: Psoriasis: Comorbidities. J Dermatol. 48:732–740. 2021.
11. Wan, M. T., Shin, D. B., Hubbard, R. A., Noe, M. H., Mehta, N. N., & Gelfand, J. M. (2018). Psoriasis and the risk of diabetes: A prospective population-based cohort study. Journal of the American Academy of Dermatology, 78(2), 315–322.e1.
12. Gyldenløve, M., Storgaard, H., Holst, J. J., Vilsbøll, T., Knop, F. K., & Skov, L. (2015). Patients with psoriasis are insulin resistant. Journal of the American Academy of Dermatology, 72(4), 599–605.
13. Boehncke W. H. (2018). Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Frontiers in immunology, 9, 579.
14. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91.
15. Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1.
16. Salihbegovic, E. M., Hadzigrahic, N., Suljagic, E., Kurtalic, N., Hadzic, J., Zejcirovic, A., Bijedic, M., & Handanagic, A. (2015). Psoriasis and dyslipidemia. Materia socio-medica, 27(1), 15–17.
17. Gyldenløve M, Jensen P, Linneberg A, Thyssen JP, Zachariae C, Hansen PR, et al. Psoriasis and the Framingham risk score in a Danish hospital cohort. Int J Dermatol. 2013
18. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562.
19. A. Pietrzak, I. Jastrzebska, D. Krasowska et al., “Serum pancreatic lipase [EC] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis,” Journal of Molecular Catalysis B, vol. 40, no. 3-4, pp. 144–154, 2006.
20. D. I. Wilkinson, “Lipid metabolism in psoriasis,” in Proceedings of the International Symposium on Psoriasis, E. M. Farber, A. J. Cox, and P. H. Jacobs, Eds., pp. 277–287, Stanford University Press, Stanford, Calif, USA, 1971.
21. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. NIH Public Access. 2012; 224:218–21.
22. Kimball, A. B., Szapary, P., Mrowietz, U., Reich, K., Langley, R. G., You, Y., Hsu, M. C., Yeilding, N., Rader, D. J., & Mehta, N. N. (2012). Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology, 67(1), 76–85.
23. Egeberg A., Thyssen J.P., Jensen P., Gislason G.H., Skov L. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: A nationwide cohort study. Acta Derm. Venereol. 2017; 97:819–824. doi: 10.2340/00015555-2657
24. Shiba M., Kato T., Funasako M., Nakane E., Miyamoto S., Izumi T., Haruna T., Inoko M. Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan. PLoS ONE. 2016; 11:e0149316.
25. Ghiasi, M., Nouri, M., Abbasi, A., Hatami, P., Abbasi, M. A., & Nourijelyani, K. (2011). Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian journal of dermatology, 56(5), 533–536.
26. Duan, Xi MD; Liu, Junbo MD; Mu, Yunzhu MD; Liu, Ting MD; Chen, Yujuan MD Yu, Ruichao MD; Xiong, Xincai MD; Wu, Tao MD, PhD,∗. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine 99(9):p e19303, February 2020.
27. Farshchian M, Ansar A, Sobhan M. Associations between cardiovascular risk factors and psoriasis in Iran. Clin Cosmet Investig Dermatol. 2015; 8:437–442.
28. Felming P, Kraft J, Gulliver WP, Lynde C. The relationship of obesity with the severity of psoriasis: a systematic review. J Cutan Med Surg. 2015;19(5):450–456.
29. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.
30. Hamminga EA, van der Lely AJ, Neumann HAM, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–773.